Numab Therapeutics Ag

Numab Therapeutics Ag company information, Employees & Contact Information

Explore related pages

Numab Therapeutics Ag email format Numab Therapeutics Ag management contacts

Related company profiles:

Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.

Company Details

Employees
66
Founded
-
Address
Bachtobelstrasse 5, Horgen,8810,switzerland
Phone
41445330471
Email
in****@****mab.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
numab.com
HQ
Horgen
Competitors
Tune Therapeutics, Molecular Partners, Normunity, Timberlyne Therapeutics, Umoja Biopharma, ImmunOs Therapeutics AG, Ouro Medicines, Kardigan, Windward Bio, Light Horse Therapeutics.
Looking for a particular Numab Therapeutics Ag employee's phone or email?

Numab Therapeutics Ag Questions

News

From $30m to $1.25bn: Numab CEO talks the power of saying no - BioXconomy

From $30m to $1.25bn: Numab CEO talks the power of saying no BioXconomy

Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease - GlobeNewswire

Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease GlobeNewswire

Boehringer Ingelheim advances T-cell engager from Numab collaboration - BioWorld MedTech

Boehringer Ingelheim advances T-cell engager from Numab collaboration BioWorld MedTech

Numab Therapeutics - The Pharma Letter

Numab Therapeutics The Pharma Letter

Numab Therapeutics raises $55M for antibody-based immunotherapies - Tech.eu

Numab Therapeutics raises $55M for antibody-based immunotherapies Tech.eu

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program - Business Wire

Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program Business Wire

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal - Fierce Biotech

J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights deal Fierce Biotech

Kaken Pharmaceutical and Numab Therapeutics collaborate on inflammatory bowel disease treatment - BioSpectrum Asia

Kaken Pharmaceutical and Numab Therapeutics collaborate on inflammatory bowel disease treatment BioSpectrum Asia

Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors - The Manila Times

Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors The Manila Times

Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis - Pharmaceutical Executive

Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis Pharmaceutical Executive

J&J expands atopic dermatitis scope with $1.25bn Numab antibody purchase - Pharmaceutical Technology

J&J expands atopic dermatitis scope with $1.25bn Numab antibody purchase Pharmaceutical Technology

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal - pharmaphorum

J&J snaps up atopic dermatitis drug in $1.25bn Numab deal pharmaphorum

J&J adds bispecific for atopic dermatitis via deal with Numab - BioCentury

J&J adds bispecific for atopic dermatitis via deal with Numab BioCentury

Numab Therapeutics sells subsidiary to Johnson & Johnson - Switzerland Global Enterprise

Numab Therapeutics sells subsidiary to Johnson & Johnson Switzerland Global Enterprise

Numab doses first subject in antibody therapeutic trial for AD - Clinical Trials Arena

Numab doses first subject in antibody therapeutic trial for AD Clinical Trials Arena

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant - Labiotech.eu

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant Labiotech.eu

Johnson & Johnson Pursues Global Rights to Numab Therapeutics’ AD-Targeting Bispecific Antibody in $1.25 Billion Acquisition - BioPharm International

Johnson & Johnson Pursues Global Rights to Numab Therapeutics’ AD-Targeting Bispecific Antibody in $1.25 Billion Acquisition BioPharm International

J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab - BioSpace

J&J Inks $1.25B Deal to Buy Rights to Atopic Dermatitis Candidate from Numab BioSpace

J&J makes another I&I acquisition with $1.25B deal for Numab’s Yellow Jersey - Endpoints News

J&J makes another I&I acquisition with $1.25B deal for Numab’s Yellow Jersey Endpoints News

Ono pulls trigger on deal for multispecific antibody against 'very challenging' cancer target - Fierce Biotech

Ono pulls trigger on deal for multispecific antibody against 'very challenging' cancer target Fierce Biotech

Numab partners with Boehringer Ingelheim on multi-specific antibodies - Pharmaceutical Technology

Numab partners with Boehringer Ingelheim on multi-specific antibodies Pharmaceutical Technology

Johnson & Johnson Completes Numab Subsidiary Acquisition, Boosts Bispecific Antibody Pipeline - BioPharm International

Johnson & Johnson Completes Numab Subsidiary Acquisition, Boosts Bispecific Antibody Pipeline BioPharm International

Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity - Fierce Biotech

Numab raises $111M to challenge Genmab, BioNTech for emerging PD-L1 opportunity Fierce Biotech

J&J buys Numab’s atopic dermatitis prospect for $1.25 billion - The Pharma Letter

J&J buys Numab’s atopic dermatitis prospect for $1.25 billion The Pharma Letter

J&J gains another bispecific antibody with $1.25B skin drug buy - BioPharma Dive

J&J gains another bispecific antibody with $1.25B skin drug buy BioPharma Dive

J&J to acquire Numab’s Yellow Jersey Therapeutics in deal worth $1.25bn - PMLiVE

J&J to acquire Numab’s Yellow Jersey Therapeutics in deal worth $1.25bn PMLiVE

Numab nabs Novo in $110m series C - - Global Venturing

Numab nabs Novo in $110m series C - Global Venturing

J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition - MedCity News

J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition MedCity News

J&J buys Numab’s lead atopic dermatitis bispecific for $1.25B - BioWorld MedTech

J&J buys Numab’s lead atopic dermatitis bispecific for $1.25B BioWorld MedTech

Numab makes room for series B funding - - Global Venturing

Numab makes room for series B funding - Global Venturing

Numab Therapeutics expands I-O research collaboration with Ono Pharma - The Pharma Letter

Numab Therapeutics expands I-O research collaboration with Ono Pharma The Pharma Letter

Numab, Kaken Establish Deal for Multispecific Antibody for Inflammatory Disease - Genetic Engineering and Biotechnology News

Numab, Kaken Establish Deal for Multispecific Antibody for Inflammatory Disease Genetic Engineering and Biotechnology News

JnJ to buy rights to Numab Therapeutics Clinical-Stage Bispecific Antibody NM26 - Medical Dialogues

JnJ to buy rights to Numab Therapeutics Clinical-Stage Bispecific Antibody NM26 Medical Dialogues

Numab AG bags CHF70m in licencing deal - European Biotechnology Magazine

Numab AG bags CHF70m in licencing deal European Biotechnology Magazine

Numab Gets Asthma Candidate Back from Sucampo - Genetic Engineering and Biotechnology News

Numab Gets Asthma Candidate Back from Sucampo Genetic Engineering and Biotechnology News

Companies like Numab Therapeutics Ag

Windward Bio logo - Similar company to Numab Therapeutics Ag

Windward Bio

25
Ouro Medicines logo - Similar company to Numab Therapeutics Ag

Ouro Medicines

16
Molecular Partners logo - Similar company to Numab Therapeutics Ag

Molecular Partners

175
Kardigan logo - Similar company to Numab Therapeutics Ag

Kardigan

108
ImmunOs Therapeutics AG logo - Similar company to Numab Therapeutics Ag

Immunos Therapeutics Ag

13
Normunity logo - Similar company to Numab Therapeutics Ag

Normunity

24
Timberlyne Therapeutics logo - Similar company to Numab Therapeutics Ag

Timberlyne Therapeutics

13
Umoja Biopharma logo - Similar company to Numab Therapeutics Ag

Umoja Biopharma

201
Light Horse Therapeutics logo - Similar company to Numab Therapeutics Ag

Light Horse Therapeu...

35
Tune Therapeutics logo - Similar company to Numab Therapeutics Ag

Tune Therapeutics

80

Top Numab Therapeutics Ag Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant